Abivax Stock: Weekly Record, Supported by a New All-Time High
This week, the performance of Abivax stock has been remarkable on the Euronext Paris, showing a significant outperformance compared to the main market indices. At the center of attention, the biotech company has experienced dynamic trading sessions, benefiting from a favorable context following the publication of positive medical results. The annual trend remains dominated by an impressive surge, illustrated by new stock market highs.
Weekly Performance Overview
Abivax closed the week at a price of €94.20, marking a weekly change of 7.53%. This positive momentum is well above that of the CAC 40, which recorded a rise of 2.58% over the same period, and the SBF 120 at 2.52%. Over the year, the stock's performance has reached 886.4%, with a remarkable acceleration since the publication of positive results for one of the company's drugs in development earlier in the month. This progression places the company among the strongest growths of the year on the Paris stock exchange. The weekly journey was marked by new highs recorded during the sessions, reaching a high of €94.70. Volatility remains, with a range of nearly €7 between the weekly extremes (€87.20 to €94.70). Some profit-taking occurred in the second half of the week, without questioning the overall movement. The evolution of circulating capital, reflecting activity on the stock, suggests a continuation of significant exchanges, even though volumes traditionally slow down during acceleration phases.
Technical Analysis Insights
From a technical standpoint, Abivax is now moving beyond its main technical thresholds. The stock maintains well above its 50-day and 200-day moving averages, which are respectively at €78.56 and €33.68, indicating a solid underlying bullish trend. The resistance threshold, set at €94.20, has been tested several times, with the stock approaching the upper limit of the Bollinger Bands at €95.84. The one-month volatility stands at 17.02, reflecting the intensity of variations in the stock. Momentum indicators confirm the dynamism of the value. The RSI at 66 indicates the strength of the upward movement, without yet showing extreme tension on the stock. The positive MACD line reinforces this view, steering the stock towards territories rarely explored this year. The presence of a beta of -0.81 suggests that the stock's behavior is out of sync with market trends, reinforcing the atypical nature of its recent trajectory.
